-
Gene therapy approaches that involve the genetic modification of human haematopoietic stem cells have the potental to engineer HIV control by introducing cells resistant to HIV infection, the 20th Conference on Retroviruses and Opportunistic Infections ...
13 March 2013 | Gus Cairns
-
The next-generation integrase
inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for
treatment-experienced people with resistance to two or more antiretroviral drug
classes, researchers reported in a poster presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week ...
10 March 2013 | Liz Highleyman
-
Omitting nucleoside reverse transcriptase inhibitors (NRTIs)
when switching from a non-suppressive regimen to a new combination with at
least two active agents can reduce pill burden and side-effects without
compromising effectiveness, researchers reported yesterday at the 20th Conference on Retroviruses and Opportunistic
Infections ...
07 March 2013 | Liz Highleyman
-
Tenofovir alafenamide fumarate or TAF (formerly
GS-7340), a new pro-drug of the widely used NRTI tenofovir, reaches cells
harbouring HIV more easily than the older tenofovir disoproxil fumarate (TDF), allowing
for similar antiviral efficacy with smaller doses and with ...
07 March 2013 | Liz Highleyman
-
A
next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI),
MK-1439, demonstrated robust antiretroviral activity and good tolerability as
monotherapy in a small phase Ib clinical study, researchers reported yesterday
at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
NNRTIs are generally well ...
06 March 2013 | Liz Highleyman
-
Cenicriviroc,
which blocks both CCR5 and CCR2 receptors on immune cells, is effective against
HIV, better tolerated than current antiretrovirals and has immunomodulatory
activity that may reduce inflammation, according to a presentation yesterday at
the 20th Conference on Retroviruses and Opportunistic Infections (CROI ...
06 March 2013 | Liz Highleyman
-
Running out of antiretroviral treatment options may severely curtail the life expectancy of people with HIV in resource-rich countries, according to Australian research published in the online edition of AIDS. The research expands upon a study ...
22 January 2013 | Michael Carter
-
Several studies, or updates of studies, comparing newer against
older drug regimens were presented at the Eleventh International Congress on Drug Therapy
in HIV Infection last week.
Amongst them were the 48-week results from the STAR study, an
open-label ...
20 November 2012 | Gus Cairns
-
The integrase
inhibitor S/GSK1265744 exhibited
potent and prolonged activity against a broad range of HIV subtypes, was active
against clones with resistance to raltegravir (Isentress) and elvitegravir, and appears to have a high barrier to
resistance, according to a presentation ...
17 September 2012 | Liz Highleyman
-
The
experimental integrase inhibitor dolutegravir combined with abacavir/lamivudine
(Kivexa or Epzicom) demonstrated statistically superior antiviral efficacy
than the popular Atripla
single-tablet regimen for first-line HIV treatment, largely because fewer
people stopped using the former regimen due to side-effects, researchers
reported this week ...
14 September 2012 | Liz Highleyman
Get set for HIV treatmentA tool to help you decide whether you are ready to start taking HIV treatment.
HIV, GPs & other primary careThis booklet explains the services GPs offer, how this fits with HIV specialist care, and how to make the most of primary care services.
Treatment as prevention – free webinar 20 March 2013As
part of its European HIV prevention work, NAM is collaborating...
Microbicides research – free webinar 22 February 2013As
part of its European HIV prevention work, NAM is collaborating...
HIV treatment update – Winter 2013 21 February 2013The new edition of HIV treatment update (HTU) is on...